



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/759,328	
			Filing Date	January 16, 2004	
			First Named Inventor	Said M. Sebti	
			Art Unit	1636-1633	
Examiner Name	Maria Marvich, Ph.D.				
Attorney Docket Number	USF-T144XCZ1				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MM	U1	US-11/274,368	11-14-2005	Sebti (patent application)	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	- Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F					
	F					
	F					
	F					
	F					
	F					
	F					

Examiner Signature	M Marvich	Date Considered	3/29/06
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/759,328	
			Filing Date	January 16, 2004	
			First Named Inventor	Said M. Sebti	
			Group Art Unit	1036-1633	
			Examiner Name	Maria Marvich, Ph.D.	
			Attorney Docket Number	USF-T144XCZ1	
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MM	R1	SUN, J. <i>et al.</i> "Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine" <i>Cancer Res.</i> , 1999, 59:4919-4926.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		


Examiner Signature	<i>mmarvich</i>	Date Considered	3/29/06
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/759,328	
			Filing Date	January 16, 2004	
			First Named Inventor	Said M. Sebti	
			Group Art Unit	1633	
			Examiner Name	Maria B. Marvich, Ph.D.	
Sheet	1	of	2	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
MM	R1	ADAMSON, P. <i>et al.</i> "Post-translational modifications of p21 <sup>ras</sup> proteins" <i>J Biol Chem</i> , 1992, 267:20033-20038.			
	R2	ADNANE, J. <i>et al.</i> "RhoB, not RhoA, represses the transcription of the transforming growth factor $\beta$ type II receptor by a mechanism involving activator protein 1" <i>J Biol Chem</i> , 2002, 277:8500-8507.			
	R3	ARMSTRONG, S.A. <i>et al.</i> "CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB" <i>J Biol Chem</i> , 1995, 270:7864-7868.			
	R4	BARON, R. <i>et al.</i> "RhoB prenylation is driven by the three carboxylterminal amino acids of the protein: Evidenced <i>in vivo</i> by an anti-farnesyl cysteine antibody" <i>Proc Natl Acad Sci USA</i> , 2000, 97:11626-11631.			
	R5	CHANG, F. <i>et al.</i> "Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention" <i>Leukemia</i> , 2003, 17:1263-1293.			
	R6	CHARDIN, P. <i>et al.</i> "Coding sequence of human <i>rho</i> cDNAs clone 6 and clone 9" <i>Nucleic Acids Res.</i> 1988, 16: 2717.			
	R7	CLARK, E.A. <i>et al.</i> "Genomic analysis of metastasis reveals an essential role for RhoC" <i>Nature</i> , 2000, 406:532-535.			
	R8	DOWNWARD, J. "Targeting Ras signaling pathways in cancer therapy" <i>Nat Rev Cancer</i> , 2003, 3:11-22.			
	R9	FORGET, M.A. <i>et al.</i> "The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers" <i>Clin Exp Metastasis</i> , 2002, 19(1):9-15.			
	R10	FRITZ, G. and KAINA, B. "Ras-related GTPase RhoB represses NF- $\kappa$ B signaling" <i>J Biol Chem</i> , 2001, 276:3115-3122.			
	R11	FUKATA, M. <i>et al.</i> "Roles of Rho-family GTPases in cell polarisation and directional migration" <i>Curr Opin Cell Biol</i> , 2003, 15:590-597.			
	R12	GENBANK accession number X06820, "H. sapiens rhoB gene mRNA" October 24, 1996.			
MM	R13	GENBANK accession number CAA29968, "rhoB [Homo sapiens]" October 24, 1996.			

Examiner Signature	M. Marvich	Date Considered	3/29/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/759,328	
			Filing Date	January 16, 2004	
			First Named Inventor	Said M. Sebtì	
			Group Art Unit	1633	
			Examiner Name	Maria B. Marvich, Ph.D.	
Sheet	2	of	2	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MM	R14	JIANG, K. <i>et al.</i> "Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis" <i>Mol Cell Biol</i> , 2004, 24:5565-5576.	
	R15	JIANG, K. <i>et al.</i> "EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation" <i>Oncogene</i> , 2004, 23:1136-1145.	
	R16	LEBOWITZ, P.F. <i>et al.</i> "Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription" <i>J Biol Chem</i> , 1997, 272:16093-16095.	
	R17	LIU, A-X. <i>et al.</i> "RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells" <i>Mol Cell Biol</i> , 2001, 21:6906-6912.	
	R18	MAZIERES, J. <i>et al.</i> "Loss of RhoB expression in human lung cancer progression" <i>Clin Cancer Res</i> , 2004, 10:2742-2750.	
	R19	NAKAMURA, T. <i>et al.</i> "Cloning of the RhoB gene from the mouse genome and characterization of its promoter region" <i>Biochem. Biophys. Res. Commun.</i> , 1996, 226(3):688-694.	
	R20	NOBES, C.D. and HALL, A. "Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia" <i>Cell</i> , 1995, 81:53-62.	
	R21	SEBTI, S.M. and HAMILTON, A.D. "Inhibition of Ras prenylation: A novel approach to cancer chemotherapy" 1997, 74:103-114.	
	R22	SYMONS, M. and RUSK, N. "Control of vesicular trafficking by Rho GTPases" <i>Curr Biol</i> , 2003, 13:R409-418.	
	R23	WANG, D-A and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor suppressive and apoptotic activities" Presentation at the American Association for Cancer Research, Anaheim, CA, April 16-20, 2005, abstract.	
	R24	WANG, D-A. and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities" <i>J. Biol. Chem.</i> , 2005, 280:19243-19249.	
MM	R25	WELSH, C.F. "Rho GTPases as key transducers of proliferative signals in G <sub>1</sub> cell cycle regulation" <i>Breast Cancer Res Treat</i> , 2004, 84:33-42.	
	R		

Examiner Signature	M Marvich	Date Considered	3/29/06
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/759,328
				Filing Date	January 16, 2004
				First Named Inventor	Said M. Sebti
				Art Unit	1636-1633
				Examiner Name	Maria Marvich, Ph.D.
Sheet	1	of	2	Attorney Docket Number	USF-T144XCZ1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MM	U1	US-2003-0018003 A1	01-23-2003	Sebti	All
MM	U2	US-2002-0034725 A1	03-21-2002	McKenna et al.	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	M. Marvich	Date Considered	3/29/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/759,328
Filing Date	January 16, 2004
First Named Inventor	Said M. Sebt
Group Art Unit	1636 1633
Examiner Name	Maria Marvich, Ph.D.
Attorney Docket Number	USF-T144XCZ1

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
mm	R1	ADJEI, A.A. "Ras signaling pathway proteins as therapeutic targets" <i>Curr Pharm Design</i> , 2001, 7:1581-1594.	
	R2	CAPONIGRO, F. "Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy?" <i>Anti-Cancer Drugs</i> , 2002, 13:891-897.	
	R3	END, D.W. <i>et al.</i> "Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 <i>in vivo</i> and <i>in vitro</i> " <i>Cancer Res.</i> , 2001, 61:131-137.	
	R4	GURA, T. "Systems for identifying new drugs are often faulty" <i>Science</i> , 1997, 278:1041-1042.	
	R5	KERBEL, R.S. "Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans" <i>Cancer Biol. &amp; Ther.</i> , 2003, 2(4 Supp. 1):S134-S139.	
	R6	REUTER, C.W. <i>et al.</i> "Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?" <i>Blood</i> , 2000, 96:1655-1669.	
	R7	ROBSON, T. and HIRST, D. "Transcriptional targeting in cancer gene therapy" <i>J. Biomed. Biotech.</i> , 2003, 2:110-137.	
	R8	SHI, B. <i>et al.</i> "The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes <i>in vitro</i> and enhances their antitumor activity <i>in vivo</i> " <i>Cancer. Chemother. Pharmacol.</i> , 2000, 46:387-393.	
mm	R9	VOSKOGLUO-NOMIKOS, T. <i>et al.</i> "Clinical predictive value of the <i>in vitro</i> cell line, human xenograft, and mouse allograft preclinical cancer models" <i>Clin. Cancer Res.</i> , 2003, 9:4227-4239.	
mm	R10	Office Action mailed 06/28/2005 in U.S. Serial No. 10/649,602, filed February 15, 2002.	
	R		
	R		
	R		

Examiner  
Signature

mm

Date  
Considered

3/29/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

replacement page  
1449 6/6/05

PTO/SB/088 (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/759,328
		Filing Date	January 16, 2004
		First Named Inventor	Said M. Sebti
		Group Art Unit	1636
		Examiner Name	
Sheet	4	of	5
		Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MM	R40	QIU, R.G. et al. <i>Nature</i> , 1995, 374:457-459.	
	R41	MELLOR, H. et al. <i>J. Biol. Chem.</i> , 1998, 273:4811-4814.	
	R42	ZHANG, F.L. et al. <i>Annu. Rev. Biochem.</i> , 1998, 65:241-269.	
	R43	LEBOWITZ, P.F. et al. <i>J. Biol. Chem.</i> , 1997, 272:15591-15594.	
	R44	SEBTI, S.M. et al. <i>Pharmacol. Ther.</i> , 1997, 272:15591-15594.	
	R45	GIBBS, J.B. et al. <i>Annu. Rev. Pharmacol. Toxicol.</i> , 1997, 37:143-166.	
	R46	COX, A.D. et al. <i>Biochim. Biophys. Acta.</i> , 1997, 1333:F51-F71.	
	R47	LEBOWITZ, P.F. et al. <i>Oncogene</i> , 1998, 17:1439-1445.	
	R48	CHEN, Z. et al. "Farnesylated and geranylgeranylated RhoB suppress the transformation of PANC-1 human pancreatic cancer cells" Proceedings of the 91 <sup>st</sup> Annual Meeting of the American Association of Cancer Research, Vol. 14, page 220, abstract no. 1402. 2000	
	R49	LIU and JESSELL "A role for rhoB in the delamination of neural crest cells from the dorsal neural tube" <i>Development</i> , 1998, 125:5055-5067.	
	R50	LEBOWITZ et al. "Farnesyltransferase inhibitors alter the prenylations and growth-stimulating function of RhoB" <i>JBC</i> , 1997, 272(25):15591-15594.	
	R51	MENG and EL-DEIRY "Tumor suppressor genes as targets for cancer gene therapy" <i>Gene Therapy of Cancer</i> , Chapter 1, pages 3-18. (1999)	
MM	R52	VERMA and SOMIA "Gene therapy-promises, problems and prospects" <i>Nature</i> , 1997, 389:239-242.	

Examiner Signature	<i>MMarich</i>	Date Considered	5/25/05
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.